Login to Your Account



Dressed Up and Ready to Partner

Ardelyx Raises $30M Series B For Lead Drug RDX5791 Trials

By Tom Wall


Thursday, September 1, 2011
Ardelyx Inc. closed a $30 million Series B preferred stock financing that the company said will help fund completion by early 2012 of an ongoing 180-patient Phase II trial of lead candidate RDX5791 in patients with constipation-predominant irritable bowel syndrome (IBS-C) and a dose-ranging/regimen study of RDX5791 for prevention of excess dietary sodium absorption to control hypertension.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription